CeriBell’s Quiet Period Will Expire on November 20th (NASDAQ:CBLL)

CeriBell’s (NASDAQ:CBLL) quiet period will end on Wednesday, November 20th. CeriBell had issued 10,606,060 shares in its initial public offering on October 11th. The total size of the offering was $180,303,020 based on an initial share price of $17.00. During CeriBell’s quiet period, insiders and underwriters that worked on the IPO are restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on CBLL shares. Bank of America initiated coverage on shares of CeriBell in a research note on Tuesday, November 5th. They set a “buy” rating and a $32.00 price objective on the stock. TD Cowen assumed coverage on CeriBell in a research note on Tuesday, November 5th. They set a “buy” rating and a $31.00 target price on the stock. Canaccord Genuity Group began coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued a “buy” rating and a $30.00 target price for the company. William Blair assumed coverage on CeriBell in a research note on Tuesday, November 5th. They set an “outperform” rating for the company. Finally, Canaccord Genuity Group raised their price target on shares of CeriBell from $30.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, CeriBell has a consensus rating of “Buy” and an average target price of $31.20.

CeriBell Stock Down 1.2 %

Shares of CBLL opened at $27.55 on Friday. CeriBell has a twelve month low of $23.00 and a twelve month high of $29.53.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($1.03). The business had revenue of $17.20 million during the quarter, compared to analysts’ expectations of $17.06 million. Research analysts predict that CeriBell will post -1.55 earnings per share for the current fiscal year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.